P A Vasey

Summary

Affiliation: University of Glasgow
Country: UK

Publications

  1. ncbi request reprint Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee
    P A Vasey
    CRC Department of Medical Oncology, Beatson Oncology Centre, Glasgow, United Kingdom
    Clin Cancer Res 5:83-94. 1999
  2. ncbi request reprint Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer
    P A Vasey
    Beatson Oncology Centre and Stobhill Hospital, Glasgow, United Kingdom
    J Clin Oncol 20:1562-9. 2002
  3. ncbi request reprint Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trials Group
    P A Vasey
    Cancer Research Campaign Department of Medical Oncology, Beatson Oncology Centre, Western Infirmary, Glasgow, United Kingdom
    J Clin Oncol 17:2069-80. 1999
  4. pmc Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer
    P A Vasey
    CRC Department of Medical Oncology, Beatson Oncology Centre, Western Infirmary, Glasgow, G11 6NT
    Br J Cancer 84:170-8. 2001
  5. pmc A dose-finding study of carboplatin-epirubicin-docetaxel in advanced epithelial ovarian cancer
    V J O'Neill
    Cancer Research UK Department of Medical Oncology, Beatson Oncology Centre, Western Infirmary, Glasgow GL1 6NT, UK
    Br J Cancer 86:1385-90. 2002
  6. pmc Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies
    P A Vasey
    Cancer Research UK, Department of Medical Oncology, Beatson Oncology Centre, Western Infirmary, Glasgow G11 6NT, UK
    Br J Cancer 89:S23-8. 2003
  7. pmc Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer
    P A Vasey
    Department of Medical Oncology, Cancer Research UK, West of Scotland Clinical Trials Unit, Beatson Oncology Centre, E Block, Western Infirmary, Glasgow, G11 6NT, Scotland, UK
    Br J Cancer 87:1072-8. 2002
  8. ncbi request reprint A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate
    A C McDonald
    CRC Department of Medical Oncology, Beatson Oncology Centre, Glasgow, United Kingdom
    Clin Cancer Res 4:605-10. 1998
  9. pmc A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers
    P A Vasey
    CR UK Clinical Trials Unit, Beatson Oncology Centre, Western Infirmary, Dumbarton Road, Glasgow, Scotland G11 6NT, UK
    Br J Cancer 98:1774-80. 2008
  10. doi request reprint Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial
    S V Barrett
    Department of Medical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK
    Ann Oncol 19:898-902. 2008

Detail Information

Publications15

  1. ncbi request reprint Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee
    P A Vasey
    CRC Department of Medical Oncology, Beatson Oncology Centre, Glasgow, United Kingdom
    Clin Cancer Res 5:83-94. 1999
    ..The recommended Phase II dose is 280 mg/m2 every 3 weeks. Studies are planned in colorectal, NSCLC, and breast cancer patients...
  2. ncbi request reprint Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer
    P A Vasey
    Beatson Oncology Centre and Stobhill Hospital, Glasgow, United Kingdom
    J Clin Oncol 20:1562-9. 2002
    ....
  3. ncbi request reprint Docetaxel and cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. Scottish Gynaecological Cancer Trials Group
    P A Vasey
    Cancer Research Campaign Department of Medical Oncology, Beatson Oncology Centre, Western Infirmary, Glasgow, United Kingdom
    J Clin Oncol 17:2069-80. 1999
    ..The primary end point was the incidence of severe fluid retention that necessitated treatment withdrawal...
  4. pmc Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer
    P A Vasey
    CRC Department of Medical Oncology, Beatson Oncology Centre, Western Infirmary, Glasgow, G11 6NT
    Br J Cancer 84:170-8. 2001
    ..3-19.1). Recommended doses are carboplatin AUC 5 (via(51)Cr EDTA) or AUC 6 (if calculated) plus docetaxel 75 mg/m(2). A randomized trial comparing this regimen with carboplatin-paclitaxel has just completed recruitment...
  5. pmc A dose-finding study of carboplatin-epirubicin-docetaxel in advanced epithelial ovarian cancer
    V J O'Neill
    Cancer Research UK Department of Medical Oncology, Beatson Oncology Centre, Western Infirmary, Glasgow GL1 6NT, UK
    Br J Cancer 86:1385-90. 2002
    ..The predefined maximum tolerated dose was exceeded in cohort 3. The cohort 4 dose level (epirubicin 50 mg m(-2), carboplatin AUC 4, docetaxel 75 mg m(-2)), warrants further study...
  6. pmc Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies
    P A Vasey
    Cancer Research UK, Department of Medical Oncology, Beatson Oncology Centre, Western Infirmary, Glasgow G11 6NT, UK
    Br J Cancer 89:S23-8. 2003
    ....
  7. pmc Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer
    P A Vasey
    Department of Medical Oncology, Cancer Research UK, West of Scotland Clinical Trials Unit, Beatson Oncology Centre, E Block, Western Infirmary, Glasgow, G11 6NT, Scotland, UK
    Br J Cancer 87:1072-8. 2002
    ..These findings establish a recommended dose of docetaxel 75 mg m(-2) in combination with cyclophosphamide 600 mg m(-2) every three weeks for phase II evaluation...
  8. ncbi request reprint A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate
    A C McDonald
    CRC Department of Medical Oncology, Beatson Oncology Centre, Glasgow, United Kingdom
    Clin Cancer Res 4:605-10. 1998
    ..9 +/- 38.8 ml/min/m2, with plasma concentrations declining with a mean harmonic terminal half-life of 1.4 +/- 0.98 h. When given by this schedule, LY231514 is tolerable, and Phase II studies are in progress...
  9. pmc A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers
    P A Vasey
    CR UK Clinical Trials Unit, Beatson Oncology Centre, Western Infirmary, Dumbarton Road, Glasgow, Scotland G11 6NT, UK
    Br J Cancer 98:1774-80. 2008
    ..Further investigation of erlotinib in epithelial ovarian carcinoma may be warranted, particularly as maintenance therapy...
  10. doi request reprint Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial
    S V Barrett
    Department of Medical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK
    Ann Oncol 19:898-902. 2008
    ..We sought to test the hypothesis that obesity reduces survival in a large, well-characterised and relatively homogeneous cohort of ovarian cancer patients...
  11. pmc SCOTROC 2A: carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer
    P A Vasey
    CR UK Clinical Trials Unit, Beatson Oncology Centre, Western Infirmary, Dumbarton Road, Glasgow G11 6NT, Scotland, UK
    Br J Cancer 94:62-8. 2006
    ..Larger phase III studies are required to test these combinations...
  12. ncbi request reprint "Dose dense" chemotherapy in ovarian cancer
    P A Vasey
    School of Medicine, University of Queensland, Herston, Queensland, Australia
    Int J Gynecol Cancer 15:226-32. 2005
    ..This article will review the clinical data supporting dose density as a therapeutic maneuver in ovarian cancer...
  13. pmc A phase II trial of capecitabine (Xeloda) in recurrent ovarian cancer
    P A Vasey
    Beatson Oncology Centre, Western Infirmary, Glasgow G11 6NT, UK
    Br J Cancer 89:1843-8. 2003
    ..The convenience and improved safety profile of capecitabine compared with intravenous. regimens make it an ideal agent for administration in the outpatient setting...
  14. doi request reprint Ovarian cancer: front-line standard treatment in 2008
    P A Vasey
    Division of Medicine, University of Queensland, Brisbane, Australia
    Ann Oncol 19:vii61-6. 2008
  15. ncbi request reprint ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of epithelial ovarian carcinoma
    P A Vasey
    Division of Oncology, Royal Brisbane and Women s Hospital, Herston, Brisbane, Queensland 4029, Australia
    Ann Oncol 16:i13-5. 2005